Earl Martin Douglas Sells 22,900 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Earl Martin Douglas sold 22,900 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $1.76, for a total transaction of $40,304.00. Following the transaction, the senior vice president directly owned 564,948 shares of the company’s stock, valued at $994,308.48. This represents a 3.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Allogene Therapeutics Stock Down 9.4%

Shares of ALLO opened at $1.63 on Friday. The stock has a market cap of $366.31 million, a P/E ratio of -1.66 and a beta of 0.60. The business’s 50 day moving average price is $1.52 and its 200-day moving average price is $1.32. Allogene Therapeutics, Inc. has a 52 week low of $0.86 and a 52 week high of $3.78.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. On average, equities analysts anticipate that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on the stock. UBS Group started coverage on shares of Allogene Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $8.00 price objective on the stock. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Allogene Therapeutics in a research note on Friday, October 10th. Wall Street Zen raised shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Citigroup raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday, January 9th. Finally, Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research note on Friday, January 9th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Allogene Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $8.40.

Allogene Therapeutics News Summary

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: Company-reported progress in its CAR‑T trials and an update indicating an extended cash runway sparked a recent rally by reducing near‑term financing risk and keeping clinical milestones on the radar. Article Title
• Neutral Sentiment: Allogene announced participation in two investor conferences in Q1 2026 — a standard IR activity that gives the company chances to update investors but is not itself a catalyst for immediate clinical progress. Article Title
• Neutral Sentiment: Broader sector commentary highlights rapid innovation in immunotherapy and AI-driven oncology R&D — a positive backdrop for Allogene but not an immediate company‑specific driver. Article Title
• Negative Sentiment: Multiple insider sales were filed for Feb. 2 (including CEO David D. Chang selling ~95,269 shares at ~$1.80 and several C‑suite/SVP sales reported at ~$1.72–1.77). While each sale is a modest percentage of individual holdings, the cluster of senior executive sales is likely increasing selling pressure and contributing to today’s pullback. Article Title

Institutional Investors Weigh In On Allogene Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Savant Capital LLC purchased a new stake in Allogene Therapeutics during the 3rd quarter valued at $27,000. Russell Investments Group Ltd. grew its holdings in shares of Allogene Therapeutics by 11,159.8% in the third quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock worth $27,000 after acquiring an additional 21,650 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in shares of Allogene Therapeutics in the third quarter worth $30,000. Caitong International Asset Management Co. Ltd increased its position in Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock valued at $30,000 after acquiring an additional 23,599 shares during the last quarter. Finally, Brighton Jones LLC lifted its holdings in Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock valued at $31,000 after acquiring an additional 11,311 shares during the period. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.